Standard
Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial. / Schmidt, Henrik; Brown, Janet; Mouritzen, Ulrik; Selby, Peter; Fode, Kirsten; Svane, Inge Marie; Cook, Graham P; Mollerup, David Hal; Geertsen, Poul F.
In:
Clinical Cancer Research, Vol. 16, No. 21, 01.11.2010, p. 5312-9.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Schmidt, H, Brown, J, Mouritzen, U, Selby, P, Fode, K
, Svane, IM, Cook, GP, Mollerup, DH & Geertsen, PF 2010, '
Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial',
Clinical Cancer Research, vol. 16, no. 21, pp. 5312-9.
https://doi.org/10.1158/1078-0432.CCR-10-1809APA
Schmidt, H., Brown, J., Mouritzen, U., Selby, P., Fode, K.
, Svane, I. M., Cook, G. P., Mollerup, D. H., & Geertsen, P. F. (2010).
Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial.
Clinical Cancer Research,
16(21), 5312-9.
https://doi.org/10.1158/1078-0432.CCR-10-1809Vancouver
Schmidt H, Brown J, Mouritzen U, Selby P, Fode K
, Svane IM et al.
Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial.
Clinical Cancer Research. 2010 Nov 1;16(21):5312-9.
https://doi.org/10.1158/1078-0432.CCR-10-1809Author
Schmidt, Henrik ; Brown, Janet ; Mouritzen, Ulrik ; Selby, Peter ; Fode, Kirsten ; Svane, Inge Marie ; Cook, Graham P ; Mollerup, David Hal ; Geertsen, Poul F. / Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 21. pp. 5312-9.
Bibtex
@article{4210c3503e20446587dd14619d4b5e3d,
title = "Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial",
abstract = "This phase I study in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of s.c. treatment of human recombinant interleukin 21 (IL-21).",
author = "Henrik Schmidt and Janet Brown and Ulrik Mouritzen and Peter Selby and Kirsten Fode and Svane, {Inge Marie} and Cook, {Graham P} and Mollerup, {David Hal} and Geertsen, {Poul F}",
note = "{\textcopyright}2010 AACR.",
year = "2010",
month = nov,
day = "1",
doi = "http://dx.doi.org/10.1158/1078-0432.CCR-10-1809",
language = "English",
volume = "16",
pages = "5312--9",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research (A A C R)",
number = "21",
}
RIS
TY - JOUR
T1 - Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial
AU - Schmidt, Henrik
AU - Brown, Janet
AU - Mouritzen, Ulrik
AU - Selby, Peter
AU - Fode, Kirsten
AU - Svane, Inge Marie
AU - Cook, Graham P
AU - Mollerup, David Hal
AU - Geertsen, Poul F
N1 - ©2010 AACR.
PY - 2010/11/1
Y1 - 2010/11/1
N2 - This phase I study in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of s.c. treatment of human recombinant interleukin 21 (IL-21).
AB - This phase I study in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of s.c. treatment of human recombinant interleukin 21 (IL-21).
U2 - http://dx.doi.org/10.1158/1078-0432.CCR-10-1809
DO - http://dx.doi.org/10.1158/1078-0432.CCR-10-1809
M3 - Journal article
VL - 16
SP - 5312
EP - 5319
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 21
ER -
